Better Therapeutics Posts Encouraging Data Establishing Proof-Of-Concept For Prescription Digital Therapy Platform

Better Therapeutics Inc BTTX announced topline results of the first-ever study evaluating the feasibility of using a prescription digital therapeutic to reduce liver fat and improve liver disease biomarkers in Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).
The study included a cohort of 22 patients and assessed changes in a range of exploratory liver biomarkers.
The LivVita study met its primary endpoint, showing a statistically significant positive signal with an average relative reduction in MRI-Proton Density Fat Fraction of 16% in the intent-to-treat population (N=19).
A statistically significant mean reduction in liver enzymes was observed.
A statistically significant mean change in FAST Score of 20%.
No severe adverse events or device-related adverse events.
High engagement and patient satisfaction were observed with the treatment.
In September, Better Therapeutics submitted an FDA de novo classification request seeking approval for BT-001 digital therapeutic designed to use cognitive behavioral therapy to treat Type 2 Diabetes (T2D) in adult patients.
Price Action: BTTX shares are up 2.11% at $1.45 on the last check Thursday.